These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

485 related articles for article (PubMed ID: 26546432)

  • 1. Enhanced SLC34A2 in breast cancer stem cell-like cells induces chemotherapeutic resistance to doxorubicin via SLC34A2-Bmi1-ABCC5 signaling.
    Ge G; Zhou C; Ren Y; Tang X; Wang K; Zhang W; Niu L; Zhou Y; Yan Y; He J
    Tumour Biol; 2016 Apr; 37(4):5049-62. PubMed ID: 26546432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects and mechanisms of SLC34A2 on maintaining stem cell-like phenotypes in CD147
    Lv Y; Wang T; Fan J; Zhang Z; Zhang J; Xu C; Li Y; Zhao G; He C; Meng H; Yang H; Wang Z; Liu J; Chen J; Wang L
    Tumour Biol; 2017 Apr; 39(4):1010428317695927. PubMed ID: 28381172
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects and mechanisms of SLC34A2 on tumorigenicity in human non-small cell lung cancer stem cells.
    Jiang Z; Hao Y; Ding X; Zhang Z; Liu P; Wei X; Xi J
    Tumour Biol; 2016 Aug; 37(8):10383-92. PubMed ID: 26846105
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultrasound reverses chemoresistance in breast cancer stem cell like cells by altering ABCG2 expression.
    Guo L; Zheng P; Fan H; Wang H; Xu W; Zhou W
    Biosci Rep; 2017 Dec; 37(6):. PubMed ID: 28935760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. SLC34A2 regulates miR-25-Gsk3β signaling pathway to affect tumor progression in gastric cancer stem cell-like cells.
    Zhang L; Guo X; Zhang L; Yang F; Qin L; Zhang D; Qin Y
    Mol Carcinog; 2018 Mar; 57(3):440-450. PubMed ID: 29178392
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expression and significance of insulin-like growth factor-1 receptor and its pathway on breast cancer stem/progenitors.
    Chang WW; Lin RJ; Yu J; Chang WY; Fu CH; Lai A; Yu JC; Yu AL
    Breast Cancer Res; 2013 May; 15(3):R39. PubMed ID: 23663564
    [TBL] [Abstract][Full Text] [Related]  

  • 7. STAT3 as a promising chemoresistance biomarker associated with the CD44
    Moreira MP; da Conceição Braga L; Cassali GD; Silva LM
    Exp Cell Res; 2018 Feb; 363(2):283-290. PubMed ID: 29352988
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Hedgehog signalling pathway mediates drug response of MCF-7 mammosphere cells in breast cancer patients.
    He M; Fu Y; Yan Y; Xiao Q; Wu H; Yao W; Zhao H; Zhao L; Jiang Q; Yu Z; Jin F; Mi X; Wang E; Cui Z; Fu L; Chen J; Wei M
    Clin Sci (Lond); 2015 Nov; 129(9):809-22. PubMed ID: 26201092
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Reduced SLC27A2 induces cisplatin resistance in lung cancer stem cells by negatively regulating Bmi1-ABCG2 signaling.
    Su J; Wu S; Tang W; Qian H; Zhou H; Guo T
    Mol Carcinog; 2016 Nov; 55(11):1822-1832. PubMed ID: 26513225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A recombinant protein TmSm(T34A) can inhibit proliferation and proapoptosis to breast cancer stem cells(BCSCs) by down-regulating the expression of Cyclin D1.
    Ma X; Zhang Y; Kang Y; Li L; Zheng W
    Biomed Pharmacother; 2016 Dec; 84():373-381. PubMed ID: 27668537
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduced miR-128 in breast tumor-initiating cells induces chemotherapeutic resistance via Bmi-1 and ABCC5.
    Zhu Y; Yu F; Jiao Y; Feng J; Tang W; Yao H; Gong C; Chen J; Su F; Zhang Y; Song E
    Clin Cancer Res; 2011 Nov; 17(22):7105-15. PubMed ID: 21953503
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pygo2 activates MDR1 expression and mediates chemoresistance in breast cancer via the Wnt/β-catenin pathway.
    Zhang ZM; Wu JF; Luo QC; Liu QF; Wu QW; Ye GD; She HQ; Li BA
    Oncogene; 2016 Sep; 35(36):4787-97. PubMed ID: 26876203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Preliminary study of the effects of β-elemene on MCF-7/ADM breast cancer stem cells.
    Dong Y; Li L; Wang L; Zhou T; Liu JW; Gao YJ
    Genet Mol Res; 2015 Mar; 14(1):2347-55. PubMed ID: 25867381
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Downregulation of CXCR7 inhibits proliferative capacity and stem cell-like properties in breast cancer stem cells.
    Tang X; Li X; Li Z; Liu Y; Yao L; Song S; Yang H; Li C
    Tumour Biol; 2016 Oct; 37(10):13425-13433. PubMed ID: 27460092
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differentiation of breast cancer stem cells by knockdown of CD44: promising differentiation therapy.
    Pham PV; Phan NL; Nguyen NT; Truong NH; Duong TT; Le DV; Truong KD; Phan NK
    J Transl Med; 2011 Dec; 9():209. PubMed ID: 22152097
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Curcumin Improves the Tumoricidal Effect of Mitomycin C by Suppressing ABCG2 Expression in Stem Cell-Like Breast Cancer Cells.
    Zhou Q; Ye M; Lu Y; Zhang H; Chen Q; Huang S; Su S
    PLoS One; 2015; 10(8):e0136694. PubMed ID: 26305906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin mediates induction of miR-708 to inhibit self-renewal and chemoresistance of breast cancer stem cells through targeting CD47.
    Tan W; Tang H; Jiang X; Ye F; Huang L; Shi D; Li L; Huang X; Li L; Xie X; Xie X
    J Cell Mol Med; 2019 Sep; 23(9):5994-6004. PubMed ID: 31273952
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Expression of breast cancer resistance protein and p-glycoprotein in residual breast cancer tissue after chemotherapy and its correlation with cancer stem cells].
    Qu HB; Fan YM; Han ML; Luo HJ; Xie J; Liu H; Liu H; Wu CY; Tang WX
    Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2013 Apr; 35(2):171-6. PubMed ID: 23643006
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NFκBP65 transcription factor modulates resistance to doxorubicin through ABC transporters in breast cancer.
    Velaei K; Samadi N; Soltani S; Barazvan B; Soleimani Rad J
    Breast Cancer; 2017 Jul; 24(4):552-561. PubMed ID: 27878697
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Diallyl Disulfide Inhibits Breast Cancer Stem Cell Progression and Glucose Metabolism by Targeting CD44/PKM2/AMPK Signaling.
    Xie X; Huang X; Tang H; Ye F; Yang L; Guo X; Tian Z; Xie X; Peng C; Xie X
    Curr Cancer Drug Targets; 2018; 18(6):592-599. PubMed ID: 29110616
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.